Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical and nutritional products. The Company had two segments: Pharmaceuticals and Nutritionals. The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business. The Nutritionals segment consists of Mead Johnson Nutritionals (Mead Johnson), primarily an infant formula and children's nutritionals business. In June 2008, BMS acquired Kosan Biosciences, Inc., a developer of oncology products. In August 2008, the Company completed the divestiture of its ConvaTec business to Cidron Healthcare Limited, an affiliate of Nordic Capital Fund VII and Avista. In December 2008, BMS completed the sale of its brand business in Egypt to GlaxoSmithKline. In July 2009, the Company's branded generics business, which comprises a portfolio of 13 branded pharmaceuticals was acquired by GlaxoSmithKline pl
Bristol Myers Squibb Co.
NYSE:BMY ISIN:US1101221083
新闻
日本的大正制药株式会社(TYO:4535) 周三表示,将收购百时美施贵宝公司(Bristol-Myers Squibb Co.)(NYSE:BMY) 在亚太地区(不包括中国和日本)价值3.1亿美元的非处方药业务。
###
19,049 公司背景浏览
- 本页浏览人次: (过去7日: 23) (过去30日: 100) (自发布以来: 5602)